The involvement of nutraceuticals to sustainable heathcare in Europe in the context of major depressive disorder (MDD), Dr. Nahlaa A. Khalifa and Dr. Elham A. Aljaaly
Purpose: Study evidence-based records on some effective nutraceuticals to be involve in Europe in Major Depression Disorder (MDD) management. Represent nutraceuticals anti-depressant properties to achieve the European health policy targets ‘Investing in Health’ and upkeep sustainable healthcare systems.
Methodology: Gaining literature by searching MEDLINE (PubMed), Google Scholar, PsychINFO and Quertile databases
and retrieving relevant published articles in the peer-reviewed journals.
Findings: Results provided evidence of a range of nutraceuticals, which are of potential benefits in management of depression. Studies support the anti-depressant properties of S-Adenosyl Methionine (SAMe), Folnic acid, 5-hydroxytryptophan (5-HTP) and omega-3 fatty acids. The results might give evidence for innovative adjunctive neurobiological line for managing and treating depression in Europe.
Practical implications: Randomised controlled trials and evaluation process continue to provide evidence for the nutraceuticals use for depression.
Social implications: Nutraceuticals emphasise the Person-focused Medicine, which offers a psychophysical balance to the individual.
Originality/value: Nutraceuticals have specific antidepressant properties that found to be of benefit in psychiatric population and reduce the pharmacotherapeutic side effects.
Keywords: Complementary and Alternative Medicine, CAM, Nutraceuticals, Depression, Anti-depressant, S-Adenosyl Methionine, SAMe, Folic Acid, 5-hydroxytryptophan, 5-HTP, Omega-3, Sustainability, Europe.